Inclusion Criteria:

- Have a diagnosis of advanced-stage potentially fatal illness. As well as metastatic
cancer this may include autoimmune, neurological, infectious or rheumatoid diseases
as well. The participant must have a probability of survival of more than six months.
The estimated life expectancy in relation to the study must be documented.

- The participant makes the decision to participate in the study by his or her own will
and that there is no inhibition to his or her will or ability of deciding due to the
primary disease.

- Meet DSM-IV criteria for Anxiety Disorder as indicated by the SCID or have a score of
at least 40 on each part of the STAI.

- Have failed to respond adequately or at all to medication or psychotherapy intended
to reduce anxiety, or have refused to take anxiolytic medication.

- May be diagnosed with another affective disorder other than anxiety disorder, except
bipolar-I disorder.

- Are at least 18 years of age.

- Are willing to commit to medication dosing, experimental sessions, follow-up
sessions, and to complete evaluation instruments (although they may withdraw from the
study at any time without cause).

- Are willing to withdraw from taking any psychiatric medications during the
experimental session period. Drugs must be discontinued long enough before the first
LSD treatment session to avoid the possibility of a drug-drug interaction (the
interval will be at least 5 times the particular drug's half-life).

- If in ongoing psychotherapy, those recruited into the study may continue to see their
outside therapist, provided they sign a release for the investigators to communicate
directly with their therapist. Participants should not change therapists, increase or
decrease the frequency of therapy or commence any new type of therapy until after the
evaluation session 2 months after the second LSD treatment session.

- Participants must agree that, for one week preceding each LSD treatment session:

- a. Clinical judgment will be used to determine permissible herbal supplements.

- b. They will not initiate any new prescription medications (except with prior
approval of the research team).

- c. Clinical judgment will be used to determine permissible nonprescription
medications.

- Participants must be willing to follow restrictions and guidelines concerning
consumption of food, beverages and nicotine the night before and just prior to each
LSD session.

Exclusion Criteria:

- Women who are pregnant or nursing, or of child bearing potential and are not
practicing an effective means of birth control.

- Anyone with past or present diagnosis with a primary psychotic disorder.

- Meeting DSM-IV criteria for Dissociative Disorder or Bipolar-I Affective Disorder.

- Meeting DSM-IV criteria for abuse of or dependence on any substance (other than
caffeine or nicotine) in the past 60 days.

- Diagnosed with significant somatic problems, that in the clinical judgment of the
investigators poses too great a potential for side effects.

- No sufficient liver function at the baseline examination or the day before the
experimental sessions.

- Having evidence of CNS affection from the primary disease (e.g. brain metastasis),
shown by neurocognitive impairment.

- Weighing less than 45 kg.

- Reasonably judged to present a serious suicide risk or who are likely to require
psychiatric hospitalization during the course of the study.

- Unable to fully understand the potential risks and benefits of the study and give
informed consent.

- Requiring ongoing concomitant therapy with a psychotropic drug (other than as needed,
anxiety medications, and pain control medications) and are unable or unwilling to
comply with the washout period.